Abstract 219P
Background
Radical radiotherapy is the mainstay of bladder preservation treatment for muscle-invasive bladder cancer (MIBC) patients. The concurrent use of radiosensitisers improves patient outcome (Caffo et al., 2016, Hoskin et al., 2010). However, different factors may preclude patients from receiving radiosensitisers. This retrospective study evaluates the survival and toxicity outcomes of bladder preservation treatment in a tertiary cancer centre.
Methods
Patients treated with radical radiotherapy from 2010 to 2017 were divided into two groups depending on whether they received radiosensitisers in addition to radiotherapy. The primary outcome was overall survival (OS) and the secondary outcome was rate of late toxicities. Kaplan-Meier analyses were used to analyse OS. Late genitourinary (GU) and gastrointestinal (GI) toxicities were defined as treatment-related toxicities at 1-year post-treatment, assessed on the LENT/SOMA scale.
Results
A total of 428 patients were included in the survival analysis. 303 patients had combination treatment while 125 patients had radiotherapy alone. Patients in the combination group were younger (median age 72 vs 81, p < 0.001), have better performance status (PS 0-2 298 (95%) vs 115 (92%), p < 0.001), and fewer comorbidities compared to patients in radiotherapy alone group. The median follow-up for this study was 56 months. The median OS was 76 months (95% CI: 66-NA) in radiosensitiser group compared to 13 months in radiotherapy only group (95% CI: 13-21) (p < 0.001, HR = 3.09 (95% CI: 2.32-4.12)). As shown in the table, the incidence of late toxicity was low in both groups and formal analysis could not be carried out.
Table: 219P Rates of late toxicities following radical radiotherapy
Combination (N = 303) | Radiotherapy (N = 125) | |
---|---|---|
GU Toxicity | ||
Any grade | 119 (39.3%) | 2 (1.6%) |
Grade 3-4 | 4 (1.3%) | 1 (0.8%) |
GI Toxicity | ||
Any grade | 133 (43.9%) | 2 (1.6%) |
Grade 3-4 | 4 (1.3%) | 0 (0%) |
Conclusions
The survival outcome with radiosensitisation in this real-world retrospective study is in keeping with published data. Bladder preservation is effective with minimal long-term toxicities. Patients with localised MIBC should be offered the option of bladder preservation treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Radiotherapy-Related Research Group, The Christie Hospital NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster display session
Resources:
Abstract
530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
Presenter: Carla Emille Barbon
Session: Poster display session
Resources:
Abstract
531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Presenter: Byoung Chul Cho
Session: Poster display session
Resources:
Abstract
532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
Presenter: Daniel Shao Weng Tan
Session: Poster display session
Resources:
Abstract
533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
Presenter: Darren Lim
Session: Poster display session
Resources:
Abstract
534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)
Presenter: Kohei Otsubo
Session: Poster display session
Resources:
Abstract
535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)
Presenter: Satoshi Ikeda
Session: Poster display session
Resources:
Abstract
536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Presenter: James C-H Yang
Session: Poster display session
Resources:
Abstract
YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone
Presenter: Gusti Harti
Session: Poster display session
Resources:
Abstract